New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
08:24 EDTTKMRTekmira Ebola drug could see emergency use in U.S., says Maxim
Maxim said the FDA's decision to change its full clinical hold on TKM-Ebola to a partial hold paves the way for potential emergency use of the drug in the U.S., if needed. Maxim noted that Tekmira's DOD contract for development of the treatment is initially worth $140M, adding that the firm expect Tekmira to receive a government supplier contract by 2018 for the drug. Maxim keeps its Buy rating and $23 price target on the stock.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent TKMR news | >>
October 20, 2014
09:09 EDTTKMREMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
October 19, 2014
16:44 EDTTKMREbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTTKMRCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTTKMRBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTTKMRSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 15, 2014
15:34 EDTTKMRTekmira TKM-HBN preclinical study shows 'knockdown of HBV surface antigen'
Subscribe for More Information
10:49 EDTTKMREbola linked names rise again amid broader market sell-off
Subscribe for More Information
09:57 EDTTKMRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:58 EDTTKMRTekmira volatility up, 2nd Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 14, 2014
11:19 EDTTKMRNIH says several potential Ebola treatments under development
Subscribe for More Information
10:10 EDTTKMRNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTTKMRChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
05:40 EDTTKMRTekmira partner Alnylam reports positive clinical data for Patisiran study
Tekmira Pharmaceuticals (TKMR) reported that Alnylam Pharmaceuticals (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension, or OLE, study in patients with Familial Amyloidotic Polyneuropathy, or FAP. Patisiran is an RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, which is enabled by Tekmira's lipid nanoparticle, or LNP, technology. Alnylam presented data at the American Neurological Association's 2014 Annual Meeting. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics.
October 13, 2014
07:12 EDTTKMROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTTKMRPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTTKMRCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTTKMRNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTTKMRTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
10:54 EDTTKMRMapp looking to up production of experimental Ebola treatment, WSJ says
Mapp Biopharmaceutical is aiming to broaden the manufacturing of its experimental Ebola treatment, ZMapp, according to The Wall Street Journal, citing comments from the company. Mapp said that the treatment was given to a few infected individuals prior to supplies running out two months ago. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
1 | 2 | all recent TKMR news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use